← Leaderboards
Xiangrong Kong
Johns Hopkins University
$16,389,124
Attributed
$16,631,064
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.2M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,631,064 · 4
By mechanism
UG1$15,187,946 · 1
K25$515,065 · 1
R34$483,881 · 1
R21$444,172 · 1
Top collaborators
- Peter A Campochiaro2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Barry R Zirkin$13,871,792
- Sunil Suhas Solomon$14,104,351
- David D. Celentano$57,488,358
- Peter A Campochiaro$21,020,539
- Chris Beyrer$53,118,025
Others in their field
Top investigators on “Data Collection”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$578,168,859
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$414,261,438
- David Heimbrook · Leidos Biomedical Research, Inc.$318,215,888
- Marian Ewell · The Emmes Company, Llc$276,352,498
Research focus
Data CollectionDesignMonitorPreventAgedProgramsBlindnessResearch PersonnelVisionRandomized TrialVisual AcuityOptical Coherence TomographyIncidenceImageMaculaParticipantLeadershipMutationHuman ResourcesCause Of DeathEvaluationFutureAreaEarly Treatment
Grant awards (14)
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with retinitis pigmentosa$3,183,918
UG1 · FY2025 · EY · contact PI
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with retinitis pigmentosa$2,945,503
UG1 · FY2024 · EY · contact PI
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with retinitis pigmentosa$5,218,636
UG1 · FY2023 · EY · contact PI
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with retinitis pigmentosa$3,839,889
UG1 · FY2022 · EY · contact PI
Structure-Function Relationships in Stargardt Disease.$198,547
R21 · FY2022 · EY · contact PI
Structure-Function Relationships in Stargardt Disease.$245,625
R21 · FY2021 · EY · contact PI
Planning study for a phase-2 randomized multi-center placebo-controlled treatment trial of retinitis pigmentosa$238,256
R34 · FY2021 · EY · contact PI
Planning study for a phase-2 randomized multi-center placebo-controlled treatment trial of retinitis pigmentosa$245,625
R34 · FY2020 · EY · contact PI
Multilevel determinants of male circumcision uptake, Rakai, Uganda$63,194
K25 · FY2017 · AI · contact PI
Multilevel determinants of male circumcision uptake, Rakai, Uganda$62,532
K25 · FY2017 · AI · contact PI
Multilevel determinants of male circumcision uptake, Rakai, Uganda$81,851
K25 · FY2016 · AI · contact PI
Multilevel determinants of male circumcision uptake, Rakai, Uganda$47,902
K25 · FY2016 · AI · contact PI
Multilevel determinants of male circumcision uptake, Rakai, Uganda$129,784
K25 · FY2015 · AI · contact PI
Multilevel determinants of male circumcision uptake, Rakai, Uganda$129,802
K25 · FY2014 · AI · contact PI